ibudilast

Also Known As:

1-(2-isopropylpyrazolo(1,5-a)pyridin-3-yl)-2-methyl-1-propanone; 1-(2-isopropylpyrazolo(1,5-alpha)pyridin-3-yl)-2-methyl-1-propanone; 3-isobutyryl-2-isopropylpyrazolo(1,5-a)pyridine; AV 411; AV-411; AV411; KC 404; KC-404; MN-166; MN166

Networked: 136 relevant articles (26 outcomes, 39 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Pyrazoles: 61
      - ibudilast: 136
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indolizines: 3
      - ibudilast: 136

Experts

1.	Johnson, Kirk W: 10 articles (08/2017 - 11/2006)
2.	Fox, Robert J: 9 articles (11/2021 - 06/2015)
3.	Watkins, Linda R: 7 articles (01/2017 - 11/2006)
4.	Coffey, Christopher S: 6 articles (11/2021 - 01/2016)
5.	Klawiter, Eric C: 6 articles (11/2021 - 01/2016)
6.	Ray, Lara A: 5 articles (01/2022 - 08/2017)
7.	Matsuda, Kazuko: 5 articles (12/2021 - 01/2016)
8.	Bermel, Robert A: 5 articles (11/2021 - 01/2018)
9.	Goodman, Andrew D: 5 articles (11/2021 - 10/2016)
10.	Naismith, Robert T: 5 articles (11/2021 - 01/2018)

Related Diseases

1.	Neuralgia (Stump Neuralgia) 11/01/2006 - "Overall, the results indicate that AV411 is effective in diverse models of neuropathic pain and support further exploration of its potential as a therapeutic agent for the treatment of neuropathic pain." 08/15/2018 - "Therefore, ibudilast might be effective for chronic neuropathic pain after peripheral and central nerve damage. " 02/10/2012 - "Ibudilast could be useful for the treatment of neuropathic pain of central as well as peripheral origin." 04/01/2012 - "Inhibition of TLR4 has shown some biological effects in neuropathic pain models and ibudilast (the TLR4 pathway-inhibiting agent) has been approved for for phase 2 clinical trials. " 08/15/2018 - "We investigated whether ibudilast was effective on established allodynia associated with activated microglial phenotypes in two rat models of peripheral and central neuropathic pain. "
2.	Hypersensitivity (Allergy) 01/01/1992 - "These results suggest that ibudilast would be an effective agent for improving nonspecific airway hypersensitivity in asthmatics." 04/01/1984 - "KC-404 was shown to be effective also on type III allergic reaction." 02/10/2012 - "Ibudilast ameliorated hindpaw hypersensitivity in both SCI and CCI rats, whereas vehicle treatment had no effect. " 02/10/2012 - "Rats were treated with either ibudilast (10 mg/kg IP) or vehicle (2 mL/kg) during the period of robust and steady hindpaw hypersensitivity for each model--CCI rats were treated 14-16 days post-surgery, and SCI rats were treated 30-32 days post-surgery--and tested daily. " 01/01/2001 - "These clinical applications are based on the properties of ibudilast that inhibit platelet aggregation, improve cerebral blood flow and attenuate allergic reactions. "
3.	Inflammation (Inflammations) 01/01/2022 - "This preliminary study examined the effect of ibudilast on peripheral and potential central markers of inflammation in individuals with AUD. " 01/01/2021 - "Thus, this study substantiates the protective effect of ibudilast on FA-induced AKI in mice and suggests that protection might be achieved by reducing pyroptosis and inflammation, likely through the inhibition of TLR4-mediated NF-κB and MAPK signaling pathways." 01/01/2021 - "However, researchers have not explored whether ibudilast exerts a protective effect on AKI by inhibiting inflammation. " 01/01/2019 - "This study was undertaken to assess the therapeutic potential of ibudilast by measuring its capacity to modulate inflammation in human leukocytes and RA synovial fibroblasts (RASFs) and in experimental arthritis. " 01/01/2023 - "Repurposing ibudilast to mitigate Alzheimer's disease by targeting inflammation."
4.	Neuroinflammatory Diseases 09/11/2020 - "This study will further develop ibudilast, a safe and promising novel compound with strong preclinical and clinical safety data for AUD, and will probe biological mechanisms underlying the effects of Ibudilast on stress, neuroinflammation, and alcohol cue-reactivity and craving. " 01/01/2016 - "Ibudilast appeared to reduce reward-related subjective effects of MA in this early-stage study, possibly due to altering the processes of neuroinflammation involved in MA reward. " 01/01/2020 - "We performed a randomized, placebo-controlled trial to determine the safety and efficacy of ibudilast (IBUD), a phosphodiesterase inhibitor that reduces neuroinflammation, for the treatment of MA use disorder. " 01/01/2020 - "Randomized, Placebo-Controlled Trial of Targeting Neuroinflammation with Ibudilast to Treat Methamphetamine Use Disorder." 01/01/2016 - "The glial cell modulator ibudilast attenuates neuroinflammation and enhances retinal ganglion cell viability in glaucoma through protein kinase A signaling."
5.	Alcoholism (Alcohol Abuse) 09/11/2020 - "Ibudilast for alcohol use disorder: study protocol for a phase II randomized clinical trial." 08/01/2017 - "Development of the Neuroimmune Modulator Ibudilast for the Treatment of Alcoholism: A Randomized, Placebo-Controlled, Human Laboratory Trial." 10/01/2021 - "Non-treatment-seeking participants (n = 45) with current alcohol use disorder were randomized to receive twice-daily dosing with either ibudilast (50 mg; n = 20) or placebo (n = 25). " 10/01/2021 - "Ibudilast, a novel neuroimmune modulator being studied to treat alcohol use disorder (AUD), was shown in a randomized controlled trial (NCT03489850) to reduce ventral striatum (VS) activation in response to visual alcohol cues. " 10/01/2021 - "Ibudilast attenuates alcohol cue-elicited frontostriatal functional connectivity in alcohol use disorder."

Related Drugs and Biologics

1.	Phosphodiesterase Inhibitors
2.	Ophthalmic Solutions (Eye Drops)
3.	Phosphoric Diester Hydrolases (Phosphodiesterases)
4.	Morphine (MS Contin)
5.	Opioid Analgesics (Opioids)
6.	Oxaliplatin (Eloxatin)
7.	Retinaldehyde (Retinal)
8.	Type 4 Cyclic Nucleotide Phosphodiesterases
9.	Paclitaxel (Taxol)
10.	Lithium

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)
3.	Intravenous Administration
4.	Ligation
5.	Topical Administration